Corticosteroid treatment of refractory Kawasaki disease

Journal of Rheumatology

Volumn 33, Issue 4, 2006, Pages 803-809

  Lang, Bianca A ^a,g   Yeung, Rae S M ^b   Oen, Kiem G ^c   Malleson, Peter N ^d   Huber, Adam M ^a   Riley, Mark ^e   Ebbeson, Regan ^e   Ramsey, Suzanne E ^a   Laxer, Ronald M ^b   Silverman, Earl D ^b   McCrindle, Brian W ^b   Ratnapalan, Savithiri ^b   Feldman, Brian M ^f  

^a DALHOUSIE UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Children's and Women's Hospitals of British Columbia   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g IWK HEALTH CENTRE   (Canada)

Author keywords

Corticosteroids; Intravenous methylprednisolone; IVIG refractory Kawasaki disease; Kawasaki disease

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE;

CANADA; CLINICAL ARTICLE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DILATATION; CORTICOSTEROID THERAPY; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; FEVER; HUMAN; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; REVIEW; SCHOOL CHILD;

CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; GLUCOCORTICOIDS; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PEDIATRICS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33645837446     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Kawasaki T. Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6.
2. Melish ME, Kawasaki syndrome. Pediatr Rev 1996;17:153-62.
3. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85.
4. Burns JC, Glode MP, Kawasaki syndrome. Lancet 2004;364:533-44.
5. Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991;119:279-82.
6. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-8.
7. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7.
8. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
9. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-61.
10. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93.
11. Han RK, Sinclair B, Newman A, et al. Recognition and management of Kawasaki disease. CMAJ 2000;162:807-12.
12. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-8.
13. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease [abstract]. Pediatrics 2000;105:E78.
14. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9.
15. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9.
16. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-7.
17. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
18. Yanagawa H, Kawasaki T, Shigematsu I. Nationwide survey on Kawasaki disease in Japan. Pediatrics 1987;80:58-62.
19. Kusakawa S, Tutara K. Efficacies and risks of aspirin in the treatment of the Kawasaki disease. Prog Clin Biol Res 1987;250:401-13.
20. Kijima Y, Kamiya T, Suzuki A, Hirose O, Manabe H. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ J 1982;46:1239-42.
21. Nonaka Z, Maekawa K, Okabe T, et al. Randomized controlled study of intravenous prednisolone and gamma globulin treatment in 100 cases with Kawasaki disease. Proceedings of the Fifth International Symposium on Kawasaki Disease 1995;328-31.
22. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999;135:465-9.
23. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003;142:611-6.
24. Okada Y, Shinohara M, Kobayashi T, Inoue Y, Tomomasa T, Morikawa A. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003;143:363-7.
25. Dale RC, Saleem MA, Daw S, Dillon MJ. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr 2000;137:723-6.
26. Dajani AS, Taubert KA, Takahashi M, et al. Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Mean Association. Circulation 1994;89:916-22.
27. Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004;23:463-4.
28. Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J 2001;20:635-7.
29. Kuijpers TW, Biezeveld M, Achterhuis A, et al. Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect. Pediatrics 2003;112:986-92.
30. Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004;163:263-4.
31. Lawrence S, Burns J, Bastian Jea. Infliximab therapy for refreactory Kawasaki disease [abstract]. Pediatr Res 2003;53:1929A.
32. Petty R, Cassidy J. Polyarteris nodosa and related vasculitides. In: Cassidy JT, Petty RE, editors. Textbook of Pediatric Rheumatology. Philadelphia: WB Saunders: 2001:595-603.
33. Youssef PP, Haynes DR, Triantafillou S, et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 1997;40:1400-8.
34. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1992;89:9991-5.
35. Suzuki N, Seguchi M, Kouno C, Inukai K, Kito H, Kobayashi H. Rupture of coronary aneurysm in Kawasaki disease. Pediatr Int 1999;41:318-20.
36. Takahashi M, Mason W, Lewis AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 1987;75:387-94.
37. Sasaguri Y, Kato H. Regression of aneurysms in Kawasaki disease: a pathological study. J Pediatr 1982;100:225-31.
38. Longenecker JP, Kilty LA, Johnson LK. Glucocorticoid influence on growth of vascular wall cells in culture. J Cell Physiol 1982;113:197-202.
39. Voisard R, Seitzer U, Baur R, et al. Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. Int J Cardiol 1994;43:257-67.
40. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990;56:29-36.
41. Baylis EM, Williams IA, English J, Marks V, Chakraborty J. High dose intravenous methylprednisolone "pulse" therapy in patients with rheumatoid diseuse. Plasma methylprednisolone levels and adrenal function. Eur J Clin Pharmacol 1982;21:385-8.
42. Ichida F, Fatica NS, Engle MA, et al. Coronary artery involvement in Kawasaki syndrome in Manhattan. New York: risk factors and role of aspirin. Pediatrics 1987;80:828-35.
43. Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6.
44. Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986;108:388-92.
45. Levy M, Koren G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J 1990; 9:122-6.